Shyft Analytics, a Medidata company, has expanded the real-world evidence (RWE) components of its solution platform and added to its RWE team, which will be led by Aaron Galaznik, MD, and Bruno Lempernesse.
The team serves as a dedicated resource for customers’ data analytics and evidence generation needs, providing services including data due diligence, evidence strategy, analytics best practices consulting, as well as full study execution.
Galaznik, the new head of research, has held leadership roles at Takeda and Pfizer working to develop the companies’ real-world data (RWD) initiatives.
Previously the CEO of Inflexxion, Lempernesse in his new role as the vice president and general manager of the Shyft RWE solutions team said the company has found varying level of maturity with regards to RWE teams and capabilities at life science organizations.
“Some have fully-staffed RWE departments capable of managing large-scale real-world data sets, performing rigorous data analysis, and generating outcomes studies,” he told us. “But more often, we come across organizations that require deep expertise to support the various RWE-related needs from across the organization.”
Lempernesse said, “The expansion of this capability at Shyft allows us to provide value-added services to the industry, regardless of their current in-house capabilities.”
Medidata acquired Shyft Analytics in 2018 for $195m, creating a platform that combines clinical development with commercial and real-world data analytics.
